- Home
- ENX vs CRVS Comparison
ENX vs CRVS Comparison
Compare ENX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- CRVS
- Stock Information
- Founded
- ENX 2002
- CRVS 2014
- Country
- ENX United States
- CRVS United States
- Employees
- ENX N/A
- CRVS N/A
- Industry
- ENX Finance/Investors Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ENX Finance
- CRVS Health Care
- Exchange
- ENX Nasdaq
- CRVS Nasdaq
- Market Cap
- ENX 169.0M
- CRVS 459.0M
- IPO Year
- ENX N/A
- CRVS 2016
- Fundamental
- Price
- ENX $9.85
- CRVS $5.88
- Analyst Decision
- ENX
- CRVS Strong Buy
- Analyst Count
- ENX 0
- CRVS 4
- Target Price
- ENX N/A
- CRVS $15.00
- AVG Volume (30 Days)
- ENX 25.4K
- CRVS 565.6K
- Earning Date
- ENX 01-01-0001
- CRVS 11-11-2025
- Dividend Yield
- ENX 3.94%
- CRVS N/A
- EPS Growth
- ENX N/A
- CRVS N/A
- EPS
- ENX 0.16
- CRVS N/A
- Revenue
- ENX N/A
- CRVS N/A
- Revenue This Year
- ENX N/A
- CRVS N/A
- Revenue Next Year
- ENX N/A
- CRVS N/A
- P/E Ratio
- ENX $61.00
- CRVS N/A
- Revenue Growth
- ENX N/A
- CRVS N/A
- 52 Week Low
- ENX $7.84
- CRVS $2.54
- 52 Week High
- ENX $10.07
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- ENX 72.72
- CRVS 59.43
- Support Level
- ENX $9.38
- CRVS $5.90
- Resistance Level
- ENX $9.78
- CRVS $6.09
- Average True Range (ATR)
- ENX 0.08
- CRVS 0.33
- MACD
- ENX 0.04
- CRVS -0.02
- Stochastic Oscillator
- ENX 92.72
- CRVS 58.82
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).